Ainos, Inc.AIMD
Price (close)
$1.34
Market cap
$9.9M
P/E
—
Revenue (TTM)
$13,600
Net income
-$14.5M
Dividend yield
—
1-year total return
-61.8%
Net margin
-106283.0%
Revenue growth
-87.7%
Debt / equity
—
What Ainos, Inc. does.
Inc. (the “Company”), incorporated in the State of Texas in 1984, is a dual-platform company advancing artificial intelligence–based
smelltech technologies and immune therapeutics. Our primary strategic focus is the commercialization of our proprietary scent digitization
platform, AI Nose, while we also continue to develop therapeutic assets based on our low-dose oral interferon program, VELDONA®.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $16,563 | $594,563 | $3.5M | $122,112 | $20,729 | $124,157 |
| Net income | -$1.5M | -$3.9M | -$14.0M | -$13.8M | -$14.9M | -$14.8M |
| Free cash flow | -$499,551 | -$1.4M | -$3.7M | -$4.8M | -$5.8M | -$4.6M |
More on AIMD.
- Ainos, Inc. summary
- Ainos, Inc. financial statements
- Ainos, Inc. key metrics
- Ainos, Inc. health scores and style box
- Ainos, Inc. earnings
- Ainos, Inc. dividends
- Ainos, Inc. valuation
- Ainos, Inc. ownership and insiders
- Ainos, Inc. peers
Figures from Ainos, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.